Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Signal Transduct Target Ther. 2020 Apr 17;5(1):38. doi: 10.1038/s41392-020-0144-8.
Signal Transduct Target Ther. 2020.
PMID: 32300119
Free PMC article.
Epithelial cells mimic immune cells: a novel path toward tumor immunotherapy.
Gong R, Huang Y, Wang X, Chen X, Tian Z, Ren H.
Gong R, et al.
Cancer Biol Med. 2021 Jul 9;18(4):937-9. doi: 10.20892/j.issn.2095-3941.2020.0406. Online ahead of print.
Cancer Biol Med. 2021.
PMID: 34240590
Free PMC article.
No abstract available.
Item in Clipboard
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo.
Kang G, Hu M, Ren H, Wang J, Cheng X, Li R, Yuan B, Balan Y, Bai Z, Huang H.
Kang G, et al.
Cancer Biol Med. 2021 Apr 8;18(3):772-87. doi: 10.20892/j.issn.2095-3941.2020.0568. Online ahead of print.
Cancer Biol Med. 2021.
PMID: 33830713
Free PMC article.
Item in Clipboard
Cite
Cite